SecBot SecBot
SECBOTREPLAY Home › Report › EVAX

EVAX · Evaxion A/S announced new preclinical data demonstrating the…

Evaxion A/S · 6-K filed Apr 17, 2026 at 15:20 ET

At the news

BULLISHIMPACT 7/10

6-K filed Apr 17, 2026 at 15:20 ET

Evaxion A/S announced new preclinical data demonstrating the scalability of its AI-Immunology platform in glioblastoma, identifying endogenous retrovirus (ERV)-derived antigens as a novel target source for personalized cancer vaccines. The data, to be presented at the AACR Annual Meeting on April 22, 2026, supports a proof-of-concept for overcoming low mutational burden in glioblastoma, a key challenge in immunotherapy.

  • New data shows AI-Immunology platform can identify ERV-derived antigens in glioblastoma tumors, a novel target source absent in normal tissue.
  • Platform also identified sufficient-quality neoantigens in the majority of patients, enabling personalized vaccine design.
  • Proof-of-concept includes bioinformatic and experimental data showing immunologic responses to ERV antigens.
  • Data to be presented at AACR Annual Meeting on April 22, 2026, enhancing scientific and potential partner visibility.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access